Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SDZ 811

Next Previous
X
Search
Drug Profile

SDZ 811

Alternative Names: NIM-811; SDZ-NIM-811

Latest Information Update: 19 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antivirals
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C; HIV-1 infections

Most Recent Events

  • 30 Apr 2011 Novartis completes a phase II trial in Hepatitis C in USA, Australia, Belgium, Germany, Puerto Rico, Italy, Netherlands, Spain and Taiwan (NCT00983060)
  • 31 Mar 2011 Efficacy data from a phase I/II trial in Hepatitis C released by Novartis
  • 30 Sep 2009 Phase-II clinical trials in Hepatitis C in Australia (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top